UT Southwestern Medical Center
Cardiovascular Disease fellowship · Dallas, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas Southwestern Medical Center's research in cardiovascular disease, which the program shares with other departments and affiliated hospitals.
About The University of Texas Southwestern Medical Centerinstitution-wide cardiovascular disease research
Cardiovascular Disease publications from The University of Texas Southwestern Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
249
works per year
13th of 78 cardiovascular disease fellowship programs
+17.0%
2-year growth
36th of 78 cardiovascular disease fellowship programs
33.0%
in top 10% of field (works before 2025)
10th of 74 cardiovascular disease fellowship programs
50.6%
cited above world average
21st of 74 cardiovascular disease fellowship programs
Works per year · * 2026 so far
Cardiology and Cardiovascular Medicine · 1,295
Cardiovascular Disease research topics at The University of Texas Southwestern Medical Center
Papers in the window; each links to the list on OpenAlex.
- Heart Failure Treatment and Management 282
- Atrial Fibrillation Management and Outcomes 106
- Blood Pressure and Hypertension Studies 99
- Cardiac Valve Diseases and Treatments 86
- Cardiovascular Function and Risk Factors 70
- Heart Rate Variability and Autonomic Control 53
- Cardiomyopathy and Myosin Studies 50
- Chemotherapy-induced cardiotoxicity and mitigation 42
Most cited at The University of Texas Southwestern Medical Center since 2024
All cardiovascular disease papers there on OpenAlex
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of EchocardiographySherif F. Nagueh et al. · Journal of the American Society of Echocardiography · 2025 · PubMed · cited 438
- Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail Kosiborod et al. · The Lancet · 2024 · PubMed · cited 323
- Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Eric Deanfield et al. · The Lancet · 2024 · PubMed · cited 302
- Intensive Blood-Pressure Control in Patients with Type 2 DiabetesYufang Bi et al. · New England Journal of Medicine · 2024 · PubMed · cited 236
- Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)Steven E. Nissen et al. · New England Journal of Medicine · 2025 · PubMed · cited 185
- 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to playRachel J. Lampert et al. · Heart Rhythm · 2024 · PubMed · cited 179
- Prognostic Value of Cardiovascular Biomarkers in the PopulationFranz–Josef Neumann et al. · JAMA · 2024 · PubMed · cited 127
- PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoproteinScott M. Johnson et al. · Nature Communications · 2024 · PubMed · cited 102
- Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 PatientsMohit K. Turagam et al. · Journal of the American College of Cardiology · 2025 · PubMed · cited 84
- Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure developmentAmil M. Shah et al. · Nature Communications · 2024 · PubMed · cited 81